Navigation Links
Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
Date:5/2/2012

CAESAREA, Israel, May 2, 2012 /PRNewswire/ --

Angioslide Ltd. a provider of Embolic Capture Angioplasty solutions, today announced that it has received FDA 510(K) clearance for its new 3X100mm PROTEUS device for treating Peripheral Artery Disease in below the knee (BTK) vasculature.  The new 3/100mm device accommodates 0.014" guide-wires, which significantly broadens the potential use of PROTEUS technology.  

Angioslide's proprietary technology combines the functionality of a balloon angioplasty device with the addition of built-in embolic capture. PROTEUS is a competitive PTA (Percutaneous Transluminal Angioplasty) balloon with features similar to leading PTA balloons (deflation time, pushability, crossing profile). Then, during deflation, the PROTEUS captures and retrieves potentially harmful embolic material.  The capture of embolic material is enabled by the inward folding of the balloon, which creates a low pressure cavity. The negative pressure in this cavity generates an aspiration effect, pulling embolic material into the cavity.  When retrieved through the sheath, PROTEUS removes the captured material from the body.

Below-the-Knee (BTK) interventions are often characterized by patients with long and diffuse lesions, diabetic foot ulcers and/or Critical Limbs Ischemia (CLI).  PROTEUS 3X100 offers physicians, for the first time, the ability to capture and remove embolic material with a single device during these challenging interventions.    

"Introduction of the new dedicated, BTK, low-profile 0.014" PROTEUS platform, supports Angioslide continuing commitment to improve procedure outcomes. Distal embolic complications in this compromised group of patients further risk blood flow to the foot. PROTEUS will become a necessary device in the "tool-box" of physicians practicing "endovascular-first" approach," said Lihu Avitov, Angioslide CEO.  

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company that developed a unique Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic capture. The PROTEUS™ device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic particle capture solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs. The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, and Denver Colorado.  For more information visit our website at http://www.angioslide.com

Contact:
Shira Doron
Marketing Director
Mobile: +972-54-9011134
shirad@angioslide.com

 



'/>"/>
SOURCE Angioslide Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Angioslide Announces the European Launch of New 300 mm Long Device Allowing Treatment of Entire Superficial Femoral Artery(SFA) with One Device
2. Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture
3. Hill-Rom Announces Third Quarter 2012 Dividend
4. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
5. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
6. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
7. ConvaTec Announces Acquisition of AbViser Medical, LLC
8. Cardica Announces Fiscal 2012 Third Quarter Financial Results
9. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
10. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
11. Acella Pharmaceuticals Announces a New Addition to the Commercial Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
Breaking Medicine News(10 mins):